New combo aims to unmask cancer cells in Tough-to-Treat lymphoma
NCT ID NCT05507541
First seen Apr 28, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study is for adults with diffuse large B-cell lymphoma that has returned or stopped responding to standard treatments. The trial combines two drugs: one that helps the immune system see cancer cells (TTI-622) and another that boosts the immune attack (pembrolizumab). The goal is to find the safest dose and see if the combination can shrink or eliminate tumors. About 10 people will take part in this early-phase study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.